BTLA Agonist Antibodies Cross-Species Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of BTLA agonist antibodies that mimic the binding of HVEM to BTLA for the treatment of autoimmune diseases like lupus, and existing antibodies do not effectively bind to human, cynomolgus monkey, and murine BTLA, limiting their therapeutic potential.
Innovation Solution
Development of BTLA agonist antibodies with specific light and heavy chain variable regions that mimic HVEM binding to BTLA, demonstrating increased binding affinity and cross-reactivity with human, cynomolgus monkey, and murine BTLA, activating and enhancing BTLA-mediated signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing BTLA agonist antibodies are used, then some therapeutic effect may be achieved, but they fail to effectively bind to human, cynomolgus monkey, and murine BTLA, limiting cross-species applicability and therapeutic potential
Solution Approach 1:
The antibody is designed to bind to BTLA across multiple species (human, cynomolgus monkey, and murine) by targeting conserved epitopes in the BTLA protein structure. This universal binding capability allows the same antibody to function effectively in different species models and potential clinical applications, resolving the contradiction between cross-species adaptability and binding reliability.
2Strength
If BTLA agonist antibodies are developed to mimic HVEM binding, then binding affinity to BTLA is enhanced, but the complexity of ensuring both structural similarity to HVEM and functional agonist activity increases
Solution Approach 1:
The antibody is engineered to mimic the binding mode of HVEM to BTLA by adopting a similar structural configuration in the complementarity-determining regions (CDRs). Specifically, the CDR loops are arranged to replicate the spatial and chemical features of HVEM's binding interface, allowing the antibody to achieve high binding affinity through structural copying rather than de novo design, thereby reducing design complexity while maintaining strong binding.
3Object-affected harmful factors
If standard of care with steroids is used, then autoimmune disease symptoms are managed, but unfavorable and dangerous side effects occur
Solution Approach 1:
The BTLA agonist antibody serves as an intermediary therapeutic agent that activates the BTLA-HVEM immune checkpoint pathway to modulate immune cell activation. This mechanism provides an alternative to steroid therapy, achieving disease symptom management through targeted immune regulation rather than broad anti-inflammatory suppression, thereby avoiding steroid-related side effects while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively bind to BTLA across species, providing enhanced therapeutic benefits for autoimmune diseases by activating BTLA signaling, potentially reducing the need for steroid use and managing autoimmune disease symptoms.
Implementation Method 1
The antibodies of the present invention are expected to be useful in the treatment of autoimmune diseases such as lupus... Binding of HVEM to BTLA leads to tyrosine-phosphorylation of two conserved immunoreceptor tyrosine-based inhibitory motif domains on the cytoplasmic domain of BTLA... thus leading to suppression of immune cell activation
Data Source
AI summary
Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.